Therapeutic potential of extracellular vesicles in Parkinson’s disease-Reference-Cited by-同舟云学术

Therapeutic potential of extracellular vesicles in Parkinson’s disease

Published:2023-06-29 Issue: Volume: Page:106-122
ISSN:
Container-title:Exploration of Neuroscience
language:en
Short-container-title:Explor Neurosci

Author:

Teixeira Michelli Ramires¹^ORCID,Alievi Anderson Lucas¹^ORCID,da Costa Vitor Rodrigues²^ORCID,Dias Pinto João Rafael³^ORCID,Araldi Rodrigo Pinheiro⁴^ORCID

Affiliation:

1. Programa de Pós-Graduação em Endocrinologia e Metabologia, Escola Paulista de Medicina da Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo-SP 04023-062, Brazil

2. Programa de Pós-Graduação em Biologia Estrutural e Funcional, Escola Paulista de Medicina da Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo-SP 04039-032, Brazil

3. BioDecision Analytics Ltda., São Paulo-SP 05713-510, Brazil; Faculdade Getúlio Vargas (FGV) Management, São Paulo-SP 01452-002, Brazil †These authors contributed equally to this work.

4. Programa de Pós-Graduação em Endocrinologia e Metabologia, Escola Paulista de Medicina da Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo-SP 04023-062, Brazil; Programa de Pós-Graduação em Biologia Estrutural e Funcional, Escola Paulista de Medicina da Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo-SP 04039-032, Brazil; BioDecision Analytics Ltda., São Paulo-SP 05713-510, Brazil

Abstract

Globally, the incidence of Parkinson’s disease (PD) is increasing faster than other neurodegenerative disorders. Neuropathologically, PD is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta due to the accumulation of aggregates of misfolded α-synuclein (α-Syn) in the cytoplasm of these neurons, forming Lewy bodies. Extracellular vesicles (EVs) are associated with the spread of α-Syn to different brain areas. However, at the same time that these EVs contribute to the pathophysiology of PD, they can also be explored as therapeutic, serving as a vehicle to deliver specific molecules, since these vesicles can easily cross the blood-brain barrier. Thus, this review summarizes the recent progress in EVs as a therapeutic strategy for PD, focusing on their delivery to the brain, and discusses the potential challenges and future directions in this field.

Publisher

Open Exploration Publishing

Subject

General Medicine,General Medicine,General Medicine,General Computer Science,General Medicine,Automotive Engineering,Industrial and Manufacturing Engineering,General Earth and Planetary Sciences,General Environmental Science,General Medicine,General Medicine

Reference115 articles.

1. Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27:27–42.

2. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.

3. Zambrano K, Barba D, Castillo K, Noboa L, Argueta-Zamora D, Robayo P, et al. Fighting Parkinson’s disease: the return of the mitochondria. Mitochondrion. 2022;64:34–44.

4. Zafar S, Yaddanapudi SS. Parkinson disease. Treasure Island (FL): StatPearls Publishing; 2022.

5. de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5:525–35.